Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles by Takayuki Hosoi
Based on 36 articles published since 2008
||||

Between 2008 and 2019, T. Hosoi wrote the following 36 articles about Osteoporosis.
 
+ Citations + Abstracts
Pages: 1 · 2
1 Review [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Diagnostic criteria of primary osteoporosis and the criteria for pharmacological treatment]. 2015

Hosoi, Takayuki. ·Kenkoin Clinic, Japan. ·Clin Calcium · Pubmed #26320526.

ABSTRACT: Diagnosis of osteoporosis is based on the bone mineral density (BMD) measurement and differential diagnosis. The most important clinical determinant of bone strength is BMD in the conditions without previous fractures. It is indispensable to measure BMD to prevent first fractures. On the other hand, previous osteoporotic fractures are known to be the risk factors for other fractures. Particularly, osteoporotic vertebral fractures and hip fractures increase the risk of fractures even after the adjustment with BMD. These are the reasons why the information about previous osteoporotic fracures are important in the diagnosis of osteoporosis. In the current guideline, the patients who are given the diagnosis of primary osteoporosis are the candidates of pharmacological treatment. In addition, the patients of osteopenia one of whose parents has the history of hip fractures or those with the 10-year risk of major osteoporotic fractures of FRAX® are also considered to be the candidates of pharmacological treatment.

2 Review [Treatment goals of osteoporosis]. 2014

Hosoi, Takayuki. ·Kenkoin Clinic, Japan. ·Clin Calcium · Pubmed #24576935.

ABSTRACT: Decision in starting and modulating the treatment of osteoporosis is being done by bone mineral density prevalent fractures, bone turnover markers, and other clinical indicators. However, the goal for the treatment of osteoporosis has not been established. Currently, treat-to-target is the most urgent issue to be discussed in the field of osteoporosis. In this article, the present status of this discussion is reviewed.

3 Review [Current approach to osteoporosis]. 2013

Hosoi, Takayuki. ·National Center for Geriatrics and Gerontology, Japan. ·Clin Calcium · Pubmed #23268305.

ABSTRACT: The aim of prevention and treatment of osteoporosis is to prevent osteoporotic fractures. In the process of revising the Japanese guideline for prevention and treatment of osteoporosis and the diagnostic criteria of primary osteoporosis, the clinical significance of prevalent fragile fractures was re-considered. Recent advances in the development of the drugs for osteoporosis should be followed by the new evidences, for example about appropriate selection of the drug and duration of drug therapy. Advices to collect life style are important for the effective drug therapy as well as for the prevention of osteoporosis.

4 Review Genetic aspects of osteoporosis. 2010

Hosoi, Takayuki. ·Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Aichi, Japan. t-hosoi@ncgg.go.jp ·J Bone Miner Metab · Pubmed #20697753.

ABSTRACT: The multiple factors contributing to the pathogenesis of osteoporosis include genetic and environmental factors. Because decrease in bone mineral density (BMD) is the major clinical indicator and a useful quantitative trait, many association and linkage studies of BMD have been conducted. Although the series of studies showed apparently significant associations, the genes have not been found that can be utilized in clinical practice. Several genes identified in robust genome-wide association studies will be the new cutting edge in genetic studies of osteoporosis. Our recent reports of functional single nucleotide polymorphism in the tissue-nonspecific alkaline phosphatase gene and gamma-carboxylase gene are presented in this review to discuss the future prospects in the genetic research of osteoporosis from the point of view of genome-nutrition interaction.

5 Review [Clinical implications of undercarboxylated osteocalcin]. 2009

Hosoi, Takayuki. ·Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Japan. ·Clin Calcium · Pubmed #19949273.

ABSTRACT: Importance of vitamin K has been suggested to maintain and improve bone strength. The serum concentration of undercarboxylated osteocalcin (ucOC) is utilized to assess the vitamin K status in bone metabolism. The clinical threshold for ucOC has been determined to discriminate the people at risk for fragility fractures from the view points of vitamin K metabolism. The measurement of ucOC would be useful to select the patients who require vitamin K(2) regimen and to assess the effectiveness of vitamin K(2) therapy.

6 Review [Usefulness and limitation of FRAX in the practice of internal medicine]. 2009

Hosoi, Takayuki. ·Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Japan. ·Clin Calcium · Pubmed #19949266.

ABSTRACT: FRAX is a fracture risk assessment tool developed by WHO collaboration study. Ten-year fracture probability can be calculated by putting fracture risks on Web program. Usefulness and limitations of this algorithm should be respected in using the tool. In the practice of internal medicine, life-style modulation, secondary causes of osteoporosis and pharmacological intervention should be among the factors considered.

7 Review [Clinical decision and patient education of pharmacotherapy for osteoporosis]. 2009

Hosoi, Takayuki. ·Department of Advanced Medicine, National Center for Geriatrics and Gerontology. ·Nihon Rinsho · Pubmed #19432108.

ABSTRACT: The aim of the pharmacotherapy for osteoporosis is to prevent osteoporotic fractures. It is important to identify the patients who have the risk for fractures and to assess how high the risk is. The Japanese guideline for prevention and treatment of osteoporosis showed the criteria to start the pharmacotherapy of osteoporosis. These criteria indicated that the subjects to be treated with osteoporosis drugs are the patients diagnosed as osteoporosis according to the Japanese diagnostic criteria of osteoporosis and those of osteopenia having one of the major clinical risk factors for osteoporotic fractures. Those factors are patients' history of femoral neck fractures, excessive alcohol or tobacco smoker. Recently 10-year absolute risk for fractures can be estimated by fracture risk assessment tool by WHO group, which is named as FRAX. The way of clinical application of this tool should be discussed in each country.

8 Review [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates]. 2009

Hosoi, Takayuki. ·National Center for Geriatrics and Gerontology, Department of Advanced Medicine, Japan. ·Clin Calcium · Pubmed #19122260.

ABSTRACT: Alendronate and risedronate have been the standard regimens in the pharmacological intervention of osteoporosis based on their accumulated evidences of fracture prevention. At the start of bisphosphonate therapy, fracture risk assessment should be conducted for each patient, and the indication to use other drugs should be paid attention according to the patients' situation. At present, combination therapy with other drugs needs clinical decision at each clinical setting. A large scale prospective study is being conducted in Japan to answer the question whether the combination therapy with alendroate and alfacaldidol is more effective than alendronate alone to prevent fractures.

9 Review [Daily practice using the guidelines for prevention and treatment of osteoporosis. Fracture risk assessment with Japanese guideline]. 2008

Hosoi, Takayuki. ·National Center for Geriatrics and Gerontology, Department of Advanced Medicine. ·Clin Calcium · Pubmed #18677044.

ABSTRACT: The diagnostic criteria of osteoporosis in Japan is comprised of low bone mineral density and presence of fragile fractures as risk factors for further fractures. In addition, the importance of differential diagnosis is emphasized in this criteria. The risk factors for fragile fractures independent from low mineral density and the presence of fragile fractures were included in the criteria for pharmacotherapy in the 2006 edition of guideline for prevention and treatment of osteoporosis. These factors include smoking, excessive alcohol, and familial history of femoral neck fractures. It would be a research question whether the removal of lifestyle-related risk factors are related to the reduction of fracture risk.

10 Clinical Trial Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). 2014

Nakamura, Toshitaka / Matsumoto, Toshio / Sugimoto, Toshitsugu / Hosoi, Takayuki / Miki, Takami / Gorai, Itsuo / Yoshikawa, Hideki / Tanaka, Yoshiya / Tanaka, Sakae / Sone, Teruki / Nakano, Tetsuo / Ito, Masako / Matsui, Shigeyuki / Yoneda, Toshiyuki / Takami, Hideo / Watanabe, Ko / Osakabe, Taisuke / Shiraki, Masataka / Fukunaga, Masao. ·National Center for Global Health and Medicine (T.Nakam.), Tokyo 162-8655, Japan · Department of Medicine and Bioregulatory Sciences (T.Matsu.), University of Tokushima Graduate School of Medical Sciences, Tokushima 770-8503, Japan · Internal Medicine 1 (T.Su.), Shimane University Faculty of Medicine, Izumo 693-8501, Japan · Kenkoin Clinic (T.H.), Tokyo 104-0061, Japan · Department of Geriatric (T.Mi.), Osaka City University Medical School, Osaka 545-8585, Japan · Hori Hospital (I.G.), Yokohama 246-0021, Japan · Department of Orthopedic Surgery (H.Y.), Osaka University Graduate School of Medicine, Suita 565-0871, Japan · The First Department of Internal Medicine (Y.T.), University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan · Department of Orthopaedic Surgery Faculty of Medicine (S.T.), The University of Tokyo, Tokyo 113-8655, Japan · Department of Nuclear Medicine (T.So.), Kawasaki Medical School (M.F.), Kurashiki 701-0192, Japan · Tamana Central Hospital (T.Nakan.), Tamana 865-0064, Japan · Division of Radiology (M.I.), Nagasaki University School of Medicine, Nagasaki 852-8501, Japan · Department of Biostatistics (S.M.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan · Osaka University Graduate School of Dentistry (T.Y.), Suita 565-0871, Japan · Daiichi Sankyo Co Ltd (H.T., K.W., T.O.), Tokyo 140-8710, Japan · and Research Institute and Practice for Involutional Diseases (M.S.), Azumino 399-8101, Japan. ·J Clin Endocrinol Metab · Pubmed #24646104.

ABSTRACT: CONTEXT: Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis. OBJECTIVE: The objective of this phase 3 fracture study was to examine the antifracture efficacy and safety of denosumab 60 mg in Japanese women and men with osteoporosis compared with placebo. DESIGN AND SETTING: A randomized, double-blind, placebo-controlled trial with an open-label active comparator as a referential arm was conducted. PATIENTS: Subjects were 1262 Japanese patients with osteoporosis aged 50 years or older, who had one to four prevalent vertebral fractures. INTERVENTION: Subjects were randomly assigned to receive denosumab 60 mg sc every 6 months (n = 500), placebo for denosumab (n = 511), or oral alendronate 35 mg weekly (n = 251). All subjects received daily supplements of calcium and vitamin D. MAIN OUTCOME MEASURE: The primary endpoint was the 24-month incidence of new or worsening vertebral fracture for denosumab vs placebo. RESULTS: Denosumab significantly reduced the risk of new or worsening vertebral fracture by 65.7%, with incidences of 3.6% in denosumab and 10.3% in placebo at 24 months (hazard ratio 0.343; 95% confidence interval 0.194-0.606, P = .0001). No apparent difference in adverse events was found between denosumab and placebo during the first 24 months of the study. CONCLUSION: These results provide evidence of the efficacy and safety of denosumab 60 mg sc every 6 months in Japanese subjects with osteoporosis.

11 Clinical Trial Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). 2014

Tanaka, Shiro / Miyazaki, Teruhiko / Uemura, Yukari / Kuroda, Tatsuhiko / Miyakawa, Nobuaki / Nakamura, Toshitaka / Fukunaga, Masao / Ohashi, Yasuo / Ohta, Hiroaki / Mori, Satoshi / Hagino, Hiroshi / Hosoi, Takayuki / Sugimoto, Toshitsugu / Itoi, Eiji / Orimo, Hajime / Shiraki, Masataka. ·Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan, tanaka.shiro.8n@kyoto-u.ac.jp. ·J Bone Miner Metab · Pubmed #23828145.

ABSTRACT: Concurrent treatments with bisphosphonates and vitamin K are promising given that bisphosphonates possibly interfere with vitamin K activation. This is a prospective, multi-center, open-labeled, randomized trial of the efficacy of concurrent treatment with vitamin K2 and risedronate compared with risedronate alone and to explore subsets of patients for which concurrent treatment is particularly efficacious (trial identification number UMIN000000991). Inclusion criteria are women who meet the criteria for pharmacological therapy for osteoporosis, aged ≥65 years, have any of pre-specified risk factors, can walk unassisted, and are able to answer questionnaires. Exclusion criteria are prior warfarin use, secondary osteoporosis or non-osteoporotic metabolic bone diseases, contraindication for vitamin K2 and risedronate, hyper- or hypoparathyroidism, mental disorders, prevalent vertebral fracture at ≥6 sites, severe degenerative spinal deformation between T4 and L4, serious heart, liver, or kidney disease, or bisphosphonate use within the previous 6 months. Patients were recruited from 123 institutes between January 2008 and February 2010, and allocated to vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week) or risedronate alone (2.5 mg/day or 17.5 mg/week) groups. Primary endpoint is a vertebral or non-vertebral fracture. Secondary endpoints are bone mineral density, height, undercarboxylated osteocalcin, JOQOL, EQ-5D and safety. A sample size of 910 subjects per group and 2-year follow-up will provide 80 % power to detect 35 % risk reduction for fracture, with a two-sided significance level of 5 %. Subgroup analysis stratified to adjustment factors for random allocation, body mass index, 25-hydroxyvitamin D, estimated glomerular filtration rate, grade of vertebral fracture, JOQOL, EQ-5D, and co-morbidity is pre-specified.

12 Article Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. 2017

Cummings, Steven R / Cosman, Felicia / Lewiecki, E Michael / Schousboe, John T / Bauer, Douglas C / Black, Dennis M / Brown, Thomas D / Cheung, Angela M / Cody, Kathleen / Cooper, Cyrus / Diez-Perez, Adolfo / Eastell, Richard / Hadji, Peyman / Hosoi, Takayuki / Jan De Beur, Suzanne / Kagan, Risa / Kiel, Douglas P / Reid, Ian R / Solomon, Daniel H / Randall, Susan. ·California Pacific Medical Center, Research Institute, San Francisco, CA, USA. · Helen Hayes Hospital and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. · New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA. · Park Nicollet Institute for Research and Education, Division of Rheumatology, Minneapolis, MN, USA. · Departments of Medicine and Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. · University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA. · University of Iowa, Department of Orthopedics and Rehabilitation, Iowa City, IA, USA. · University of Toronto, Faculty of Medicine, Ontario, Canada. · Foundation for Osteoporosis Research and Education, Oakland, CA, USA. · University of Southampton, MRC Lifecourse Epidemiology Unit, Southhampton, United Kingdom. · Hospital del Mar-IMIM-Universitat Autònoma de Barcelona and RETICEF, Instituto Carlos III, Spain, Internal Medicine - Infectious Diseases, Barcelona, Spain. · University of Sheffield, Human Metabolism, England, United Kingdom. · Philipps-University of Marburg, Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Marburg, Germany. · National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, Japan. · Johns Hopkins University, Baltimore, MD, USA. · University of California, San Francisco, San Francisco, CA, USA. · Hebrew SeniorLife, Institute for Aging Research, Boston, MA, USA. · University of Auckland, Department of Medicine, Auckland, New Zealand. · Brigham and Women's Hospital, Division of Rheumatology, Boston, MA, USA. · National Osteoporosis Foundation, Arlington, VA, USA. ·J Bone Miner Res · Pubmed #27864889.

ABSTRACT: The American Society for Bone and Mineral Research and the United States National Osteoporosis Foundation (NOF) formed a working group to develop principles of goal-directed treatment and identify gaps that need to be filled to implement this approach. With goal-directed treatment, a treatment goal would first be established and choice of treatment determined by the probability of achieving that goal. Goals of treatment would be freedom from fracture, a T-score > -2.5, which is above the NOF threshold for initiating treatment, or achievement of an estimated risk level below the threshold for initiating treatment. Progress toward reaching the patient's goal would be periodically and systematically assessed by estimating the patient's compliance with treatment, reviewing fracture history, repeating vertebral imaging when indicated, and repeating measurement of bone mineral density (BMD). Using these data, a decision would be made to stop, continue, or change therapy. Some of these approaches can now be applied to clinical practice. However, the application of goal-directed treatment cannot be fully achieved until medications are available that provide greater increases in BMD and greater reduction in fracture risk than those that are currently approved; only then can patients with very high fracture risk and very low BMD achieve such goals. Furthermore, assessing future fracture risk in patients on treatment requires a new assessment tool that accurately captures the change in fracture risk associated with treatment and should also be sensitive to the importance of recent fractures as predictors of imminent fracture risk. Lastly, evidence is needed to confirm that selecting and switching treatments to achieve goals reduces fracture risk more effectively than current standard care. © 2016 American Society for Bone and Mineral Research.

13 Article Comparison of concurrent treatment with vitamin K 2017

Tanaka, Shiro / Miyazaki, Teruhiko / Uemura, Yukari / Miyakawa, Nobuaki / Gorai, Itsuo / Nakamura, Toshitaka / Fukunaga, Masao / Ohashi, Yasuo / Ohta, Hiroaki / Mori, Satoshi / Hagino, Hiroshi / Hosoi, Takayuki / Sugimoto, Toshitsugu / Itoi, Eiji / Orimo, Hajime / Shiraki, Masataka. ·Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. tanaka.shiro.8n@kyoto-u.ac.jp. · Public Health Research Foundation, Tokyo, Japan. · Biostatistics Division, Clinical Research Support Center, University of Tokyo Hospital, Tokyo, Japan. · Department of Obstetrics and Gynecology, Hori Hospital, Yokohama, Japan. · Department of Orthopedic Surgery, University of Occupational and Environmental Health School of Medicine, Fukuoka, Japan. · Kawasaki Medical School, Okayama, Japan. · Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan. · Department of Obstetrics and Gynecology, International University of Health and Welfare, Tokyo, Japan. · Bone and Joint Surgery, Seirei Hamamatu General Hospital, Shizuoka, Japan. · School of Health Science, Tottori University Faculty of Medicine, Tottori, Japan. · Kenkoin Clinic, Tokyo, Japan. · Internal Medicine 1, Shimane University Faculty of Medicine, Shimane, Japan. · Department of Orthopaedic Surgery, Tohoku University School of Medicine, Sendai, Japan. · Japan Osteoporosis Foundation, Tokyo, Japan. · Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan. ·J Bone Miner Metab · Pubmed #27484436.

ABSTRACT: The aim of this study was to investigate the efficacy of concurrent treatment with vitamin K

14 Article Effects of Fok-I polymorphism in vitamin D receptor gene on serum 25-hydroxyvitamin D, bone-specific alkaline phosphatase and calcaneal quantitative ultrasound parameters in young adults. 2015

Tanabe, Rieko / Kawamura, Yuka / Tsugawa, Naoko / Haraikawa, Mayu / Sogabe, Natsuko / Okano, Toshio / Hosoi, Takayuki / Goseki-Sone, Masae. ·Department of Food and Nutrition, Faculty of Human Sciences and Design, Japan Women's University, Tokyo, Japan. · Department of Hygienic Sciences, Kobe Pharmaceutical University, Hyogo, Japan. · Department of Child Studies, Faculty of Child Studies, Seitoku University, Chiba, Japan. · Department of Health and Nutrition Sciences, Faculty of Human Health, Komazawa Women's University, Tokyo, Japan. · Kenkoin Clinic, Tokyo, Japan. · Department of Food and Nutrition, Faculty of Human Sciences and Design, Japan Women's University, Tokyo, Japan. Email: goseki@fc.jwu.ac.jp. ·Asia Pac J Clin Nutr · Pubmed #26078251.

ABSTRACT: Several genes have been implicated as genetic determinants of osteoporosis. Vitamin D receptor (VDR) is an intracellular hormone receptor that specifically binds to the biologically active form of vitamin D, 1-alpha, 25- dihydroxyvitamin D3 [1, 25(OH)2D], and mediates its effects. One of the most frequently studied single nucleotide polymorphisms is the restriction fragment length polymorphism (RFLP) Fok-I (rs2228570). The presence of a Fok-I site, designated f, allows protein translation to initiate from the first ATG. An allele lacking the site (ATG>ACG: designated F), initiates from a second ATG site. In the present study, we explored the effect of the VDR Fok-I genotype on associations among serum bone-specific alkaline phosphatase (ALP), 25- hydroxyvitamin D3 [25(OH)D], 1, 25(OH)2D, and the dietary nutrient intake in healthy young Japanese subjects (n=193). Dietary nutrient intakes were calculated based on 3-day food records before the day of blood examinations. Quantitative ultrasound (QUS) parameters at the right calcaneus (heel bone) were measured. The allele frequencies were 0.622 for the F allele and 0.378 for the f allele in all subjects. Grouped by the VDR genotype, a significant positive correlation between the levels of serum bone-specific ALP and 25(OH)D was observed in the FF-type (p=0.005), but not in the ff-type. In addition, there was a significant positive correlation between the level of serum 25(OH)D and osteo-sono assessment index (OSI) in the FF-type (p=0.008), but not in the ff-type. These results suggest that the level of circulating 25(OH)D is an important factor when assessing the VDR Fok-I polymorphism to prevent osteoporosis.

15 Article Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). 2015

Sugimoto, T / Matsumoto, T / Hosoi, T / Miki, T / Gorai, I / Yoshikawa, H / Tanaka, Y / Tanaka, S / Fukunaga, M / Sone, T / Nakano, T / Ito, M / Matsui, S / Yoneda, T / Takami, H / Watanabe, K / Osakabe, T / Okubo, N / Shiraki, M / Nakamura, T. ·Shimane University Faculty of Medicine, Izumo, Japan. ·Osteoporos Int · Pubmed #25403903.

ABSTRACT: SUMMARY: A 12-month extension phase of DIRECT in Japanese subjects with osteoporosis showed that total 3 years of denosumab treatment in Japanese postmenopausal women and men with osteoporosis was associated with low fracture rates, persistent bone turnover marker (BTM) reductions, continuous bone mineral density (BMD) increases, and a favorable overall benefit/risk profile. INTRODUCTION: The DIRECT trial demonstrated that 2 years of treatment with denosumab 60 mg subcutaneously every 6 months significantly reduced the incidence of vertebral fracture compared to placebo in Japanese postmenopausal women and men with osteoporosis. The purpose of this study is to evaluate the efficacy and safety of denosumab treatment for up to 3 years. METHODS: This study includes a 2-year randomized, double-blind, placebo-controlled phase and a 1-year open-label extension phase in which all subjects received denosumab. The data correspond to 3 years of denosumab treatment in subjects who received denosumab (long-term group) and 1 year of denosumab treatment in subjects who received placebo (cross-over group) in the double-blind phase. RESULTS: Eight hundred and ten subjects who completed the double-blind phase enrolled into the extension phase, and 775 subjects completed the study. All subjects received denosumab with daily supplements of calcium and vitamin D. The cumulative 36-month incidences of new or worsening vertebral fractures and new vertebral fractures were 3.8 and 2.5 %, respectively, in the long-term group. In this group, the BMD continued to increase, and the reduction in BTMs was maintained. In the cross-over group, comparable BMD increases and BTMs reductions to those of in their first year of the long-term group were confirmed. Adverse events did not show a notable increase with long-term denosumab administration. One event of osteonecrosis of the jaw occurred in the cross-over group. CONCLUSIONS: Three-year denosumab treatment in Japanese subjects with osteoporosis showed a favorable benefit/risk profile.

16 Article Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture. 2014

Ohta, Hiroaki / Uemura, Yukari / Nakamura, Toshitaka / Fukunaga, Masao / Ohashi, Yasuo / Hosoi, Takayuki / Mori, Satoshi / Sugimoto, Toshitsugu / Itoi, Eiji / Orimo, Hajime / Shiraki, Masataka / Anonymous5240782. ·Department of Clinical Medical Research Center, International University of Health and Welfare, Women's Medical Center of Sanno Medical Center, Tokyo, Japan. · Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan. · National Center for Global Health and Medicine, Tokyo, Japan. · Kawasaki Medical School, Okayama, Japan. · Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Aichi, Japan. · Bone and Joint Surgery, Seirei Hamamatsu General Hospital, Shizuoka, Japan. · Internal Medicine 1, Shimane University Faculty of Medicine, Shimane, Japan. · Department of Orthopaedic Surgery, Tohoku University School of Medicine, Miyagi, Japan. · Japan Osteoporosis Foundation, Tokyo, Japan. · Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan. Electronic address: ripid@fc4.so-net.ne.jp. ·Clin Ther · Pubmed #24462224.

ABSTRACT: BACKGROUND: Deteriorated quality of life (QOL) is a major problem in osteoporotic women. However, little is known regarding the determinants of QOL in patients with osteoporosis. OBJECTIVE: Our aim was to explore the role of vitamin D status on QOL score in osteoporosis with high fracture risk. METHODS: Patients were osteoporotic women aged ≥70 years and with ≥1 risk factor for incident fracture, namely prevalent osteoporotic fracture, bone mineral density (BMD) >-3.0 SD of young adult mean, or high bone turnover marker. Health-related QOL was assessed using the Japanese Osteoporosis Quality of Life Questionnaire (JOQOL). When patients were classified into quartiles by total QOL score). Serum 25-hydroxyvitamin D (25[OH]D) level was measured by immunoassay. RESULTS: A total of 1585 osteoporotic women were included in the study (age range, 70-95 years). Age, body mass index, serum 25(OH)D status (low, normal, or high), bone mineral density, number of prevalent vertebral fractures, presence of hypertension, presence of osteoarthritis, and history of falls were significantly correlated with QOL quartile. Multivariate liner regression analysis indicated that low serum 25(OH)D level (<20 ng/mL) was an independent determinant of total QOL score quartile (P = 0.0055). The conventional determinants of QOL-age (P < 0.0001), body mass index (P = 0.0060), number of prevalent vertebral fractures (P < 0.0001), presence of osteoarthritis (P = 0.0074), and history of fall (P = 0.0098)-were also independent determinants of total QOL score. CONCLUSIONS: These results strongly suggest that low serum 25(OH)D level was a significant determinant of QOL in these osteoporotic women, independently of the conventional factors that reduce QOL. Maintenance of serum 25(OH)D levels >20 ng/mL may be required to maintain patients' QOL in osteoporosis.

17 Article [Falls and fractures]. 2013

Hosoi, Takayuki. · ·Nihon Ronen Igakkai Zasshi · Pubmed #23925087.

ABSTRACT: -- No abstract --

18 Article Diagnostic criteria for primary osteoporosis: year 2012 revision. 2013

Soen, Satoshi / Fukunaga, Masao / Sugimoto, Toshitsugu / Sone, Teruki / Fujiwara, Saeko / Endo, Naoto / Gorai, Itsuo / Shiraki, Masataka / Hagino, Hiroshi / Hosoi, Takayuki / Ohta, Hiroaki / Yoneda, Toshiyuki / Tomomitsu, Tatsushi / Anonymous4930754. ·Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, 1481-1 Otodacho, Ikoma, Nara, 630-0293, Japan. souen@nara.med.kindai.ac.jp ·J Bone Miner Metab · Pubmed #23553500.

ABSTRACT: In 1995, the Japanese Society for Bone and Mineral Metabolism (now the Japanese Society for Bone and Mineral Research) established the Osteoporosis Diagnostic Criteria Review Committee. Following discussion held at the 13th scientific meeting of the Society in 1996, the Committee, with the consensus of its members, proposed diagnostic criteria for primary osteoporosis. The Committee revised those criteria in 1998 and again in 2000. The Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis aimed at obtaining international consistency and made a revised edition based on the new findings in 2012.

19 Article Associations between serum bone-specific alkaline phosphatase activity, biochemical parameters, and functional polymorphisms of the tissue-nonspecific alkaline phosphatase gene in a Japanese population. 2013

Sogabe, Natsuko / Tanabe, Rieko / Haraikawa, Mayu / Maruoka, Yutaka / Orimo, Hideo / Hosoi, Takayuki / Goseki-Sone, Masae. ·Division of Nutrition, Department of Food and Nutrition, Faculty of Human Sciences and Design, Japan Women's University, Tokyo, Japan. ·Asia Pac J Clin Nutr · Pubmed #23353624.

ABSTRACT: INTRODUCTION: We had demonstrated that single nucleotide polymorphism (787T>C) in the tissue-nonspecific ALP (TNSALP) gene was associated with the bone mineral density (BMD). BMD was the lowest among TNSALP 787T homozygotes (TT-type) and highest among TNSALP 787T>C homozygotes (CC-type) in postmenopausal women. In the present study, we investigated the effects of the TNSALP genotype on associations among serum bonespecific alkaline phosphatase (BAP), serum calcium, and phosphorus in healthy young Japanese subjects. METHODS: Young healthy adult subjects (n=193) were genotyped for the polymorphism, and we measured the levels of serum BAP, serum calcium, and phosphorus. Dietary nutrient intakes were calculated based on 3-day food records before the day of blood examinations. RESULTS: Grouped by the TNSALP genotype, a significant negative correlation between serum BAP and phosphorus was observed in 787T>C homozygotes (CC-type), but not in heterozygotes (TCtype), nor in 787T homozygotes (TT-type). CONCLUSIONS: In the present study, we revealed that the single nucleotide polymorphism 787T>C in the TNSALP gene had effects on the correlation between serum BAP and phosphorus in young adult subjects. These results suggest that variation in TNSALP may be an important determinant of phosphate metabolism. Our data may be useful for planning strategies to prevent osteoporosis.

20 Article Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. 2012

Orimo, Hajime / Nakamura, Toshitaka / Hosoi, Takayuki / Iki, Masayuki / Uenishi, Kazuhiro / Endo, Naoto / Ohta, Hiroaki / Shiraki, Masataka / Sugimoto, Toshitsugu / Suzuki, Takao / Soen, Satoshi / Nishizawa, Yoshiki / Hagino, Hiroshi / Fukunaga, Masao / Fujiwara, Saeko. ·Japan Osteoporosis Foundation, Tokyo, Japan. ·Arch Osteoporos · Pubmed #23203733.

ABSTRACT: INTRODUCTION: In 1998, the first Japanese practice guidelines on osteoporosis was published. It has been updated several times, with the most recent being the full-scale 2011 edition and its abridged edition. The present guidelines provide information for the managements of primary osteoporosis in postmenopausal women and men over 50 years old, a summary of the evidence for the treatment of secondary osteoporosis, and a summary of the evidence for the prevention of osteoporosis in younger people. METHOD: The present Executive Summary is primarily based on the content of the 2011 Japanese abridged edition. One of the key changes is revision of the criteria for initiation of pharmacological treatment, along with an introduction of the fracture risk factors used in FRAX®. Key figures and tables were selected from the Japanese abridged edition and a reference list was added. RESULT AND CONCLUSIONS: The essential points of the Japanese practice guidelines on osteoporosis were translated into English for the first time. It is hoped that the content of the guidelines becomes known throughout the world.

21 Article [Clinical application of FRAX® in Japan]. 2012

Hosoi, Takayuki. ·Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Japan. ·Clin Calcium · Pubmed #22653025.

ABSTRACT: FRAX® is a fracture risk assessment tool developed by WHO working groups. Ten-year risks for major osteoporotic fractures or hip fracture can be calculated with FRAX®. It has been discussed how to utilize FRAX® in the clinical settings in Japan. It was necessary to recognize the performance and limitation of this tool. In the Japanese guideline for prevention and treatment of osteoporosis 2011, a threshold of 10-year risk for major osteoporotic risk was proposed for the patients with osteopenia. It is emphasized that this is the proposal to use FRAX® in addition to the result of bone mineral density measurement and is not the proposal to use FRAX® as a screening tool. The way to utilize FRAX® as a screening tool should be investigated further.

22 Article Association of CYP19 gene polymorphism with vertebral fractures in Japanese postmenopausal women. 2012

Koudu, Yasuko / Onouchi, Tsuneko / Hosoi, Takayuki / Horiuchi, Toshiyuki. ·Department of Endocrinology and Metabolism, Tokyo Metropolitan Toshima Hospital, 33-1 Sakaecho Itabashiku, Tokyo, 173-0015, Japan. ·Biochem Genet · Pubmed #22160249.

ABSTRACT: This study investigates aromatase gene polymorphism, which might influence bone strength in terms of mineral density and quality. We explored the relationship between CYP19 polymorphisms and vertebral fractures in postmenopausal Japanese women. In addition, we compared estrogen and testosterone levels in Japanese postmenopausal women with and without fractures. Osteoporotic postmenopausal women showed higher incidences of vertebral fractures than osteopenic women or women with normal lumbar bone mineral density (L2-4 BMD). Estrogen concentrations in postmenopausal women were associated with BMD; however, no association was found between sex hormone levels and the presence of fractures. The C allele rs2470152 was significantly associated with increased risk of vertebral fractures (P = 0.04), whereas none of the CYP19 polymorphisms showed differences in sex steroid levels between subjects with and without fractures. Allelic variants of aromatase genes appear to interact to influence the risk of vertebral fractures in postmenopausal Japanese women.

23 Article [Present situation of medical screening system for osteoporosis]. 2011

Yamauchi, Hirose / Sasaki, Toshiyuki / Hosoi, Takayuki. ·Japan Osteoporosis Foundation. ·Nihon Rinsho · Pubmed #21774375.

ABSTRACT: Medical screening system for osteoporosis is important method for detection of osteopenia or osteoporosis in the community. The medical screening for osteoporosis was done for female subjects at age 40, 45, 50, 55, 60, 65, 70 year-old people according to the Health Promotion Act in Japan. The number of females received the screening was 287,782 in 2008, and the number corresponded to 4.7% of the estimated numbers of subjects for the screening in the population. Sixty six percentages of institutions measured bone mass and/or bone mineral density with the purpose other than that proposed by Health Promotion Act at 2009. Calcaneus bone mass was measured in 81% of institutions by quantitative ultrasound(QUS). Because QUS is inexpensive, involves no radiation exposure, and is easily portable, this method should be suitable for medical screening for osteoporosis and its prevalent use in Japan supports this assumption.

24 Article Common variants in a novel gene, FONG on chromosome 2q33.1 confer risk of osteoporosis in Japanese. 2011

Kou, Ikuyo / Takahashi, Atsushi / Urano, Tomohiko / Fukui, Naoshi / Ito, Hideki / Ozaki, Kouichi / Tanaka, Toshihiro / Hosoi, Takayuki / Shiraki, Masataka / Inoue, Satoshi / Nakamura, Yusuke / Kamatani, Naoyuki / Kubo, Michiaki / Mori, Seijiro / Ikegawa, Shiro. ·Laboratory for Bone and Joint Diseases, Center for Genomic Medicine, RIKEN, Tokyo, Japan. ·PLoS One · Pubmed #21573128.

ABSTRACT: Osteoporosis is a common disease characterized by low bone mass, decreased bone quality and increased predisposition to fracture. Genetic factors have been implicated in its etiology; however, the specific genes related to susceptibility to osteoporosis are not entirely known. To detect susceptibility genes for osteoporosis, we conducted a genome-wide association study in Japanese using ∼270,000 SNPs in 1,747 subjects (190 cases and 1,557 controls) followed by multiple levels of replication of the association using a total of ∼5,000 subjects (2,092 cases and 3,114 controls). Through these staged association studies followed by resequencing and linkage disequilibrium mapping, we identified a single nucleotide polymorphism (SNP), rs7605378 associated with osteoporosis. (combined P = 1.51×10(-8), odds ratio = 1.25). This SNP is in a previously unknown gene on chromosome 2q33.1, FONG. FONG is predicted to encode a 147 amino-acid protein with a formiminotransferase domain in its N-terminal (FTCD_N domain) and is ubiquitously expressed in various tissues including bone. Our findings would give a new insight into osteoporosis etiology and pathogenesis.

25 Article Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. 2011

Orimo, Hajime / Nakamura, Toshitaka / Fukunaga, Masao / Ohta, Hiroaki / Hosoi, Takayuki / Uemura, Yukari / Kuroda, Tatsuhiko / Miyakawa, Nobuaki / Ohashi, Yasuo / Shiraki, Masataka / Anonymous320694. ·Health Science University, Yamanashi, Japan. ·Curr Med Res Opin · Pubmed #21554143.

ABSTRACT: OBJECTIVES: The authors conducted a randomized controlled trial to clarify the efficacy and safety of alendronate plus alfacalcidol versus alendronate alone in a clinical setting. RESEARCH DESIGN AND METHODS: Eligible patients were postmenopausal women with severe osteoporosis who were aged 70 years or older and had several risk factors for incident fractures. The primary endpoint was prevention of incident fractures, and the anti-fracture efficacy was evaluated in relation to the baseline serum 25(OH)D level. RESULTS: A total of 2164 patients were randomized to alendronate plus alfacalcidol (combination therapy) or alendronate alone (monotherapy). Although the overall difference in the incidence of vertebral fracture between the two groups was not significant, the combination therapy group had a significantly reduced risk of vertebral fractures after the first 6 months (HR, 0.53). In subgroup analyses, the combination therapy group was superior in the strata of number of prevalent vertebral fractures of ≥2 (HR, 0.51) and grade 3 of prevalent vertebral fractures (HR, 0.55). The rate of non-vertebral weight-bearing bone fractures was significantly lower in the combination therapy group than in the monotherapy group during the follow-up period (HR, 0.31). A lower baseline 25(OH)D level was associated with a higher incidence of non-vertebral weight-bearing bone fractures (HR, 3.42) despite alendronate use. Although one patient given the combination therapy had mild hypercalcemia, serious hypercalcemia and unknown adverse events were not encountered. Because of the limitations presented in this study, these results may not apply to female patients with longer than 2 years of treatments, and to male osteoporosis patients. CONCLUSIONS: The combination therapy was no more effective for overall vertebral fracture prevention. However, subgroup analysis has shown that it was more effective for fracture prevention in patients with severe vertebral deformity, multiple prevalent vertebral fractures, and for non-vertebral weight-bearing bone fracture prevention.

Next